Rodolfo Nunez-Musa*

Contract Research Organization DR (CREOR), MSc, Senior Researcher, Clinical Coordinator at Oy Med School of Medicine, Dominican Republic

*Corresponding Author: Rodolfo Nunez-Musa, Contract Research Organization DR (CREOR), MSc, Senior Researcher, Clinical Coordinator at Oy Med School of Medicine, Dominican Republic.

Received: October 05, 2024; Published: December 19, 2024

Abstract

The relationship between type 2 diabetes mellitus and cardiovascular disease is a complex and multifaceted connection that has been explored in depth by researchers over the years. The risk of developing various cardiovascular complications is significantly higher for those who have type 2 diabetes mellitus, leading to a considerable increase in morbidity and mortality rates. Cardiovascu lar disease can also have an important impact on the development and progression of diabetes, leading to a vicious cycle that worsens both conditions. Designing effective preventive and therapeutic strategies for both of them requires understanding the underlying mechanisms and shared risk factors between them. With this current paper, we pretend to elucidate the most remarkable intrinsic aspects of this relationship.

Keywords: Diabetes Mellitus; Cardiovascular; Disease; Unraveling; Interplay

References

1. Tangvarasittichai S. “Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus”. World Journal of Diabetes3 (2015): 456.
2. Menezo YJR., et al. “Oxidative stress and alterations in DNA methylation: Two sides of the same coin in reproduction”. Reproductive BioMedicine Online6 (2016): 668-683.
3. Nilsson E., et al. “Altered DNA methylation and differential expression of genes influencing metabolism and inflammation in adipose tissue from subjects with type 2 diabetes”. Diabetes9 (2015): 2962-2976.
4. Al-Haddad R., et al. “Epigenetic changes in diabetes”. Neuroscience Letters 625 (2016): 64-69.
5. Patel TP., et al. “Insulin resistance: An additional risk factor in the pathogenesis of cardiovascular disease in type 2 diabetes”. Heart Failure Reviews1 (2015): 11-23.
6. Booth GL., et al. “Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: A population-based retrospective cohort study”. The Lancet9529 (2006): 29-36.
7. Low Wang CC., et al. “Clinical update: Cardiovascular disease in diabetes mellitus”. Circulation24 (2016): 2459-2502.
8. Hou ZH., et al. “Quantification of atherosclerotic plaque volume in coronary arteries by computed tomographic angiography in subjects with and without diabetes”. Chinese Medical Journal7 (2020): 773-778.
9. Beverly JK and Budoff MJ. “Atherosclerosis: Pathophysiology of insulin resistance, hyperglycemia, hyperlipidemia, and inflammation”. Journal of Diabetes2 (2019): 102-104.
10. Robson R., et al. “Oxidative stress biomarkers in type 2 diabetes mellitus for assessment of Cardiovascular Disease Risk”. Diabetes and Metabolic Syndrome: Clinical Research and Reviews3 (2018): 455-462.
11. Wright KD., et al. “Role of adaptor protein p66shc in renal pathologies”. American Journal of Physiology-Renal Physiology2 (2018).
12. Biondi G., et al. “The P66SHC protein mediates insulin resistance and secretory dysfunction in pancreatic β-cells under lipotoxic conditions”. Diabetes 8 (2022): 1763-1771.
13. Mousavi S., et al. “The role of p66shc in diabetes: A comprehensive review from bench to bedside”. Journal of Diabetes Research (2022): 1-15.
14. Márk L and Dani G. “Diabeteses dyslipidaemia and the atherosclerosis”. Orvosi Hetilap19 (2016): 746-752.
15. Sniderman AD., et al. “Age and cardiovascular risk attributable to Apolipoprotein B, low‐density lipoprotein cholesterol or non‐high‐density lipoprotein cholesterol”. Journal of the American Heart Association10 (2016).
16. Valdivielso P., et al. “Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: A preliminary report”. Cardiovascular Diabetology1 (2009): 1.
17. Lorenzo C., et al. “Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: The insulin resistance atherosclerosis study”. The Journal of Clinical Endocrinology and Metabolism4 (2013): 1622-1630.
18. Low Wang CC., et al. “Clinical update: Cardiovascular disease in diabetes mellitus”. Circulation24 (2016a): 2459-2502.
19. Xie W., et al. “Free fatty acids inhibit TM-EPCR expression through JNK pathway: An implication for the development of the prothrombotic state in metabolic syndrome”. Journal of Thrombosis and Thrombolysis4 (2012): 468-474.
20. Lüscher TF., et al. “High-density lipoprotein”. Circulation Research1 (2014): 171-182.
21. Wang MC., et al. “Effect of blood lipid variability on mortality in patients with type 2 diabetes: A large single-center cohort study”. Cardiovascular Diabetology1 (2021).
22. Bertoluci MC and Rocha VZ. “Cardiovascular risk assessment in patients with diabetes”. Diabetology and Metabolic Syndrome 9.1 (2017).
23. Zhou JJ., et al. “Fasting glucose variation predicts microvascular risk in accord and Vadt”. The Journal of Clinical Endocrinology and Metabolism4 (2020).
24. Sardar P., et al. “Effect of intensive versus standard blood glucose control in patients with type 2 diabetes mellitus in different regions of the world: Systematic Review and meta‐analysis of Randomized Controlled Trials”. Journal of the American Heart Association5 (2015).
25. Smetana GW., et al. “To what target hemoglobin A1c level would you treat this patient with type 2 diabetes?” Annals of Internal Medicine7 (2019): 505.v
26. Strain WD., et al. “Diabetes and Frailty: An expert consensus statement on the management of older adults with type 2 diabetes”. Diabetes Therapy5 (2021): 1227-1247.
27. Nabi R., et al. “Glycation and HMG-COA reductase inhibitors: Implication in diabetes and associated complications”. Current Diabetes Reviews 3 (2019): 213-223.
28. Piarulli F., et al. “Glyco-oxidation and cardiovascular complications in type 2 diabetes: A clinical update”. Acta Diabetologica2 (2012): 101-110.
29. Potor L., et al. “Atherogenesis may involve the prooxidant and proinflammatory effects of ferryl hemoglobin”. Oxidative Medicine and Cellular Longevity (2013): 1-13.
30. Saleh J. “Glycated hemoglobin and its spinoffs: Cardiovascular disease markers or risk factors?” World Journal of Cardiology8 (2015): 449.
31. Joseph JJ., et al. “Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: A scientific statement from the American Heart Association”. Circulation9 (2022).
32. Zoungas S., et al. “Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: Evidence of glycaemic thresholds”. Diabetologia3 (2011): 636-643.
33. Harrison LB., et al. “Intensive therapy in newly diagnosed type 2 diabetes: Results of a 6-year randomized trial”. Journal of Investigative Medicine4 (2014): 676-686.
34. Kiley PJ and Storz G. “Exploiting thiol modifications”. PLoS Biology11 (2004).
35. Gerber PA and Rutter GA. “The role of oxidative stress and hypoxia in pancreatic beta-cell dysfunction in diabetes mellitus”. Antioxidants Redox Signaling10 (2017): 501-518.
36. Núñez-Musa R., et al. “Posibilidades de la Terapia Antioxidante en diabetes mellitus tipo 2. Estudio del Estrés oxidativo en una muestra poblacional de Pacientes Diabéticos”. Ciencia y Salud3 (2020): 71-93.
37. Núñez Sellés AJ., et al. “The oxidative stress index in human population with arterial hypertension and diabetes mellitus”. Journal of Pharmacy and Pharmacognosy Research2 (2019): 103-115.
38. Pickup JC and Crook MA. “Is type II diabetes mellitus a disease of the innate immune system?”
    Diabetologia10 (1998): 1241-1248.
39. Stanimirovic J., et al. “Role of C-reactive protein in diabetic inflammation”. Mediators of Inflammation (2022): 1-15.
40. Zeinolabediny Y., et al. “Monomeric C-reactive protein - a feature of inflammatory disease associated with cardiovascular pathophysiological complications?” In Vivo2 (2021): 693-697.
41. Bodman-Smith KB., et al. “C-reactive protein-mediated phagocytosis and phospholipase D signalling through the high-affinity receptor for immunoglobulin G (fcγri)”. Immunology2 (2002): 252-260.
42. Matsumori A. “Novel biomarkers of inflammation for the management of diabetes: Immunoglobulin-free light chains”. Biomedicines3 (2022): 666.
43. Ahlqvist E., et al. “Novel subgroups of adult-onset diabetes and their association with outcomes: A data-driven cluster analysis of six variables”. The Lancet5 (2018): 361-369.
44. Donath MY., et al. “Inflammation in the pathophysiology and therapy of cardiometabolic disease”. Endocrine Reviews4 (2019): 1080-1091.
45. Reyes-Farias M., et al. “White adipose tissue dysfunction in obesity and aging”. Biochemical Pharmacology 192 (2021):
46. Duewell P., et al. “NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals”. Nature7293 (2010): 1357-1361.
47. Sharma A., et al. “Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: Therapeutic implications”. Frontiers in Physiology (2018):
48. Sauter NS., et al. “Angiotensin II induces interleukin-1β-mediated islet inflammation and β-cell dysfunction independently of vasoconstrictive effects”. Diabetes4 (2014): 1273-1283.
49. Al-Mallah M., et al. “Do angiotensin converting enzyme inhibitors or angiotensin receptor blockers prevent diabetes mellitus? A meta-analysis”. Cardiology Journal5 (2010): 448-456.

Citation

Citation: Rodolfo Nunez-Musa. “Type 2 Diabetes Mellitus and Cardiovascular Disease: Unraveling the Complex Interplay (Part I of II)". Acta Scientific Gastrointestinal Disorders 8.1 (2025): 18-26.

Copyright

Copyright: © 2025 Rodolfo Nunez-Musa. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.